Quick Answer
Serina Therapeutics, Inc. reported Common Stock Shares Outstanding of 10.77 million shares for the year ending 2025.
- Serina Therapeutics, Inc. showed an increase of +14.3% in Common Stock Shares Outstanding from 2024 to 2025.
- This data is from Serina Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 25, 2026.
- XBRL data for this metric is available from 2017 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2018: 35.83 million shares | Q1 2019: 37.63 million shares | Q2 2019: 37.63 million shares | Q3 2019: 37.65 million shares | Q1 2020: 37.66 million shares | Q2 2020: 37.66 million shares | Q3 2020: 37.69 million shares | Q1 2021: 37.94 million shares | Q2 2021: 37.94 million shares | Q3 2021: 37.94 million shares | Q1 2022: 37.94 million shares | Q2 2022: 37.95 million shares | Q3 2022: 37.95 million shares | Q1 2023: 37.95 million shares | Q2 2023: 37.95 million shares | Q3 2023: 37.95 million shares | Q2 2024: 8.79 million shares | Q3 2024: 8.89 million shares | Q1 2025: 9.93 million shares | Q2 2025: 10.15 million shares | Q3 2025: 10.54 million shares.
- Over the full 10 years of available data (2017 to 2025), Serina Therapeutics, Inc.'s Common Stock Shares Outstanding has declined by 68.1%.
- Historical annual values: Fiscal year 2025: 10.77 million shares | Fiscal year 2024: 9.42 million shares | Fiscal year 2024: 8.41 million shares | Fiscal year 2023: 2.41 million shares | Fiscal year 2022: 1.08 million shares | Fiscal year 2021: 37.94 million shares | Fiscal year 2020: 37.69 million shares | Fiscal year 2019: 37.65 million shares | Fiscal year 2018: 35.83 million shares | Fiscal year 2017: 33.75 million shares.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: